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Summary
Purpose: Epilepsies in children are complex diseases. Guidelines are needed on the
appropriate use of newer versus older anti-epileptic drugs (AEDs). This paper presents
an individual patient-sampling model to assess the cost-effectiveness of using newer
AEDs as add-on therapy in line with UK prescribing guidance.
Methods: Identification of the relevant parameters and treatment pathways for the
model were achieved by a systematic review of the literature and discussions with
clinical experts. Data were obtained from the literature and supplemented with data
elicited from paediatric neurologists. The model considered paediatric patients over
the period of childhood from the age of diagnosis to 18 years.
Results: The results suggest that the older and newer AEDs are similar in terms of drug
retention rates and the average time in ‘good’ treatment outcomes. In terms of cost,
the results indicate a consistent increase in cost (compared to older AEDs) when all of
the newer AEDs are considered. The decision analysis results indicate that there are
no important health benefits from the use of newer AEDs when used as add-on therapy.
However, the analysis also reveals that the uncertainties in themodel are greater than
the differences between the drug strategies.
Conclusions: To develop guidelines on the appropriate use of newer AEDs, better
information is required from randomised controlled trials as there is insufficient data
available in the public domain to accurately estimate the nature of the trade off
between older versus newer AEDs.
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A large proportion of epilepsy syndromes start in
infancy or childhood.1 The heterogeneous and com-
plex nature of the condition presents a challenge for
diagnosis as it depends on the type of seizure (there
are many different types of focal and generalised
epileptic seizure2,3) and aetiology (symptomatic,
idiopathic and cryptogenic). Based on a review of
many studies that adopted various definitions of the
disease,4 the prevalence of epilepsy in children (up
to 15 years old) is about 5—7/1000. Some childhood
epilepsies are relatively benign, but others have a
detrimental impact on psychological, social and
intellectual development, and in severe cases the
effect on individual, carer(s) and family can be
devastating. Important consequences for children
and young people include not only the seizures
themselves but also the impact of the condition
and its effect upon social life, educational progress
and mental health.
Following a diagnosis of epilepsy in childhood,
Anti-epileptic drugs (AEDs) tend to be the first treat-
ment option considered. Over 80% of children with
epilepsyare treatedwithAEDs in theNetherlandsand
USA,5,6 and it is likely that similar practice occurs in
the United Kingdom (UK).7 Since 1989, seven
‘‘newer’’ anti-epileptic drugs (AEDs) have become
available in the UK: gabapentin, lamotrigine, leve-
tiracetam, oxcarbazepine, tiagabine, topiramate
and vigabatrin. The overall aim of AED treatment
is to reduce epileptic seizure frequency and enhance
patient’s quality of life with as few adverse effects
and as few co-medications as possible while minimis-
ing long-term detrimental effects. Few economic
studies have explored the cost-effectiveness of AEDs,
the analyses undertaken have focused more on the
overall cost of epilepsy, the effect on mortality and
the impact upon quality of life.8 Studies focusing on
the economics of childhood epilepsy are limited. A
recent review9 identified three US-based cost-out-
come studies that measured among them; the effect
of rectal diazepam used to treat severe seizures;10
the impact of reducing the numbers of AEDs given as
polytherapy;11 the cost of administering a ketogenic
diet.12 None of the studies measured the cost-effec-
tiveness of AED therapy in children newly diagnosed
with epilepsy. As the treatment of children with
epilepsy has considerations that are quite different
from adults there is a need to build a model that
exclusively considers AED therapy in children. This
paper presents a new model that explores the cost-
effectiveness of ‘newer’ AEDs in the UK, focusing on
children from the age of 3—18 years with a new
diagnosis of partial (i.e. focal) epilepsy with or with-
out secondarily generalised seizures. Given that thispaper is basedonwork commissioned for theNational
Institute of Clinical Excellence (NICE), consideration
is onlygiven touseofAEDswithin their currentUnited
Kingdom marketing authorisation (‘‘licensed’’ use).
The newer AEDs that can be used as add-on therapies
are lamotrigine, gabapentin, topiramate, oxcarba-
zepine and tiagabine. Vigabatrin is licensed for use as
add-on therapy in partial epilepsy but is recom-
mended for use only as a treatment of last resort
owing to problematic adverse effects; we therefore
did not include it in the analysis. In addition, wewere
also not able to consider tiagabine in our analysis due
to lack of data. The model therefore reports results
on the cost-effectiveness of four ‘newer’ AEDs for use
as add-on therapy.Methods
Decision problem
The ‘newer’ and ‘older’ AEDs are compared in terms
of costs and benefits, with the latter judged accord-
ing to the treatment objectives (i.e. seizure control
and favourable adverse effect profile). In order to
compare the cost-effectiveness of the ‘newer’ ver-
sus the ‘older’ AEDs, various drug sequences have
been considered, based on published prescribing
guidance in childhood epilepsy13 and advice from
clinical experts. The comparisons are between pre-
defined drug sequences that contain exclusively
‘older’ AEDs (termed older AED strategy) or a com-
bination of ‘older’ and ‘newer’ AEDs (termed newer
AED strategy). The older AED strategy is illustrated
in Fig. 1. We have assumed that all newly diagnosed
patients with partial epilepsies requiring AED treat-
ment start with monotherapy: carbamazepine fol-
lowed by sodium valproate. Depending on the
patient’s ‘response’ to sodium valproate, they then
receive either add-on therapy (sodium valproate
and carbamazepine) or the next choice monother-
apy (phenytoin). Clearly, each patient can poten-
tially be subject to many different treatment
pathways depending on the success or otherwise
of current (and past treatment). In fact, the older
AED strategy produces a possible 40 different drug
sequences that are detailed in Table 1. Note that a
drug will not be used as add-on therapy if in previous
use it led to unacceptable adverse effects or poor
seizure control. The unspecified generic older AED
described in Fig. 1 contains features of carbamaze-
pine, valproate and phenytoin, this is only consid-
ered for a patient who progresses to the end of the
drug sequence before the age of 18. The older AED
strategy represents the comparator (i.e. the base-
line option) for the newer AED strategy.
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strategy is illustrated in Fig. 2. As with the older AED
strategy many treatment pathways can be followed.
The newer AEDs are considered only as first choice
add-on therapy with sodium valproate. As in the
older AED strategy, patients still initially receive
carbamazepine and then sodium valproate; they
then move onto sodium valproate plus the ‘newFigure 1 Older drug sequence. The symbol (*) denotes drug o
was not associated with unacceptable side-effects or unacceAED’ as add-on therapy or phenytoin as monother-
apy. Separate analyses have been conducted for
each new AED — combination therapy involving
two or more newer AEDs is not considered. The
analysis therefore explores the relative cost-effec-
tiveness of each of the four newer AED strategies
with the baseline option where no newer AEDs are
available.nly used in combination if, in earlier use in this patient, it
ptable efficacy.
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Table 1 Possible drug sequences from Fig. 2
Drug sequence
cbz
cbz—val
cbz—val—phy
cbz—val—phy—old
cbz—val—val/cbz
cbz—val—val/cbz—val/phy
cbz—val—val/cbz—val/phy—val/old
cbz—val—val/cbz—phy
cbz—val—val/cbz—val/phy—old
cbz—val—val/cbz—val/phy—val/old—old
cbz—val—phy—phy/cbz
cbz—val—phy—phy/cbz—phy/val
cbz—val—phy—phy/cbz—phy/val—phy/old
cbz—val—phy—phy/cbz—old
cbz—val—phy—phy/cbz—phy/val—old
cbz—val—phy—old—old/cbz
cbz—val—phy—old—old/cbz—old/val
cbz—val—phy—old—old/cbz—old/val—old/phy
cbz—val—val/cbz—phy—phy/cbz
cbz—val—val/cbz—phy—phy/cbz—old
cbz—val—val/cbz—phy—phy/cbz—old—old/cbz
cbz—val—val/cbz—phy—phy/cbz—old—old/cbz—old/
val
cbz—val—val/cbz—phy—phy/cbz—old—old/cbz—old/
val—old/phy
cbz—val—val/cbz—phy—phy/cbz—phy/val—old
cbz—val—val/cbz—phy—phy/cbz—phy/val—old—old/
cbz
cbz—val—val/cbz—phy—phy/cbz—phy/val—old—old/
cbz—old/val
cbz—val—val/cbz—phy—phy/cbz—phy/val—old—old/
cbz—old/val—old—phy
cbz—val—val/cbz—val/phy—old
cbz—val—val/cbz—val/phy—old—old/cbz
cbz—val—val/cbz—val/phy—old—old/cbz—old/val
cbz—val—val/cbz—val/phy—old—old/cbz—old/val—
old/phy
cbz—val—val/cbz—val/phy—val/old—old—old/cbz
cbz—val—val/cbz—val/phy—val/old—old—old/cbz—
old/val
cbz—val—val/cbz—val/phy—val/old—old—old/cbz—
old/val—old/phy
cbz—val—phy—phy/cbz—old—old/cbz
cbz—val—phy—phy/cbz—old—old/cbz—old/val
cbz—val—phy—phy/cbz—old—old/cbz—old/val—old/
phy
cbz—val—phy—phy/cbz—phy/val—old—old/cbz
cbz—val—phy—phy/cbz—phy/val—old—old/cbz—old/
val
cbz—val—phy—phy/cbz—phy/val—old—old/cbz—old/
val—old/phyThe sequence of AEDs modelled in both the
older and newer AED strategies were chosen based
on published prescribing guidance13 in childhood
epilepsy and advice from clinical experts.Model structure
The treatment pathways are modelled as clinical
decisions using an individual sampling simulation
model constructed in TreeAge DATA Professional
software (Release 6). The model structure was
chosen based on published criteria for model
selection.14 It was felt that an individual sampling
model was appropriate as the drug treatment
requires a sequence of drugs to be considered,
the time frame modelled is potentially long (up to
15 years) and the model required consideration of
individuals receiving any one drug for a variable
length of time. The model structure is illustrated
in Fig. 3. A patient enters the model with a new
diagnosis of partial epilepsy. Personal character-
istics for the individual (gender, age and the
presence of learning difficulties) are then assigned
to the patient through a process of repeated
samplings from appropriate distributions for these
characteristics. The rationale behind sampling
for learning difficulties is that resource use and
quality of life will differ between the two groups.
A hypothetical cohort of children then progress
through the model and follow different clinical
pathways, based on the outcomes they experience
and the clinical decisions made. The youngest
patients at entry into the model are 3 years
(infantile epilepsy is not considered) and the old-
est are just under 18 years.
Within the model, the patient may experience
one of four treatment outcomes:1. Intolerable adverse effects, leading to early dis-
continuation (TOX).2. Lack of effect on seizure rate, leading to early
discontinuation (SEIZ).3. Partial efficacy with tolerable or no adverse-
effects (PART).4. Complete seizure freedom with tolerable or no
adverse-effects (SFREE).
Patients moving through the model will progress
through the drug sequences, the rate is deter-
mined by the treatment outcomes experienced.
Hence, patients who enter outcomes 1 or 2 will
progress to receive the next choice monotherapy
or opt to discontinue drug treatment; those enter-
ing into outcome 3 may stay on the current drug
treatment, try the next choice monotherapy or try
the next choice add-on therapy. If the patient
achieves seizure freedom (outcome 4), it is
assumed that after a given period of time (sampled
in the model), withdrawal from drug treatment
will be attempted. This assumption reflects a
desire by patients to avoid long-term use of AEDs
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Figure 2 Newer drug sequence. The symbol (*) denotes drug only used in combination if, in earlier use in this patient, it
was not associated with unacceptable side-effects or unacceptable efficacy.and the fact that approximately one third of all
epilepsies that start in childhood will, by puberty,
have shown a natural remission.15 Therefore,
patients achieving seizure freedom will either
remain on the current drug (if reluctant to with-
draw) or will attempt the withdrawal process.
Within the model, there are six possible health
states, with associated costs (Cs) and effects
(Us) to consider. Total costs and effects are thenestimated for each patient according to which of
these health states are experienced. In addition to
the four outcomes listed above, there are two
further states in the model: Patient has seizure freedom following withdrawal
of drug therapy (WFREE). Patient is not seizure free but prefers to remain
untreated (UNTRT).
104 E.J. Frew et al.
Figure 3 Patient pathway for a child with newly diagnosed partial (focal) epilepsies.Model assumptions and data
Given the complex nature of partial epilepsies in
children and the limitation of data from the pub-
lished literature, several assumptions had to be
made: Patients receiving alternative treatment in out-
comes TOX and SEIZ switch drugs rather than
receive add-on therapy. The willingness to try alternative treatment in
outcome PART depends on the number of treat-
ments tried at this point, as the number of drugs
tried increases, the patient is more likely to try
add-on therapy and less likely to try further
monotherapy options. Patients achieving seizure freedom either con-
tinue with current therapy or withdraw, they do
not switch treatments. If attempted withdrawal is unsuccessful, patients
successfully reintroduce the original drug that
achieved seizure freedom. Time to stopping an unsuccessful drug (outcomes
TOX and SEIZ) is determined by the reasons for
discontinuing and is independent of the drug. The same prescribing pattern is assumed for both
boys and girls. Policy on discontinuing and withdrawal of drugs is
the same for patients receiving monotherapy and
add-on therapy, a patient achieving complete
seizure freedom on a two drug combination would
attempt to withdraw from both drugs.
Transition probabilities relating to the effective-
ness and tolerability of the different AEDs deter-
mine the likelihood of patients reaching a particular
outcomewithin themodel. These were derived from
the systematic review of clinical effectiveness.7
Other clinical parameters for the model, such asthe proportions discontinuing treatment, time to
discontinuation or withdrawal, and likelihood of
moving onto combination therapy at each stage,
were estimated based on the epidemiological lit-
erature7 and clinical advice. For the proportions of
patients withdrawing due to adverse effects and
lack of efficacy, and for proportions achieving sei-
zure freedom, these were calculated from trial data
by obtaining the numbers withdrawing for these
reasons, adjusting the sample size for drop outs
and for length of follow up. The proportion of
patients achieving partial efficacy is assumed to
include, from the trial data, all the remaining
patients who did not withdraw for adverse effects
or lack of efficacy and did not achieve seizure free-
dom. To allow the proportion estimates to vary
according to different stages of treatment, i.e. first,
second drug attempted, essentially the trial data
available was used as ‘anchor points’ and then
various assumptions applied.7 The RCT data avail-
able for this model consist of a single trial for each
newer AED used as add-on therapy in more or less
refractory populations. The trials of add-on therapy
all included patients with variable disease history,
but the performance of placebo in these trials is
broadly similar and so we have assumed that the
trial data are reasonably representative of what will
occur at fourth-line treatment. Lamotrigine was the
only AED for which we have trial data at two dif-
ferent time points, as first line monotherapy and
later use as add-on. The proportions withdrawing
owing to toxicity are very similar in the two lamo-
trigine trials, as are the proportions withdrawing
owing to lack of effect. We have therefore kept
these parameters constant across all stages for all
AEDs. Reducing the proportion achieving complete
seizure freedom by a constant factor of 0.4 is con-
sistent with the lamotrigine data, allowing for a
small increase in efficacy when the drug is used in
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Table 2 Proportions moving into the main model outcome statesa
Outcome First-line
treatment
Second-line
treatment
Third-line
treatment
Fourth-line
treatment
Carbamazepine
1 0.113 0.113 0.113 0.113
2 0.107 0.107 0.107 0.107
3 0.153 0.529 0.679 0.739
4 0.626 0.250 0.100 0.040
Valproate
1 0.119 0.119 0.119 0.119
2 0.113 0.113 0.113 0.113
3 0.174 0.531 0.673 0.730
4 0.595 0.238 0.095 0.038
Phenytoin
1 0.125 0.125 0.125 0.125
2 0.119 0.119 0.119 0.119
3 0.192 0.531 0.666 0.721
4 0.565 0.226 0.090 0.036
Lamotrigine
1 0.062 0.062 0.062 0.062
2 0.131 0.131 0.131 0.131
3 0.238 0.579 0.716 0.770
4 0.569 0.227 0.091 0.036
Valproate + old AED
1 0.131 0.131 0.131 0.131
2 0.105 0.105 0.105 0.105
3 0.110 0.503 0.660 0.723
4 0.654 0.262 0.105 0.042
Phenytoin + old AED
1 0.137 0.137 0.137 0.137
2 0.110 0.110 0.110 0.110
3 0.131 0.504 0.653 0.713
4 0.622 0.249 0.009 0.040
Generic old AED
1 0.131 0.131 0.131 0.131
2 0.124 0.124 0.124 0.124
3 0.208 0.503 0.659 0.710
4 0.537 0.215 0.086 0.034
Gabapentin + old AED
1 0.081 0.081 0.081 0.081
2 0.266 0.266 0.266 0.266
3 0.252 0.492 0.588 0.627
4 0.401 0.160 0.064 0.026
Lamotrigine + old AED
1 0.069 0.069 0.069 0.069
2 0.123 0.123 0.123 0.123
3 0.186 0.560 0.709 0.769
4 0.622 0.249 0.100 0.040
Oxcarbazepine + old AED
1 0.143 0.143 0.143 0.143
2 0.062 0.062 0.062 0.062
3 0.225 0.567 0.704 0.759
4 0.570 0.228 0.091 0.036
Topiramate + old AED
1 0.120 0.124 0.124 0.124
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Table 2 (Continued )
Outcome First-line
treatment
Second-line
treatment
Third-line
treatment
Fourth-line
treatment
2 0.190 0.194 0.194 0.194
3 0.010 0.377 0.560 0.634
4 0.680 0.305 0.122 0.049
a 1 = Intolerable adverse effects; 2 = lack of efficacy; 3 = partial efficacy with tolerable adverse effects; 4 = complete seizure
freedom with tolerable adverse effects.combination as compared with monotherapy. The
data for first-line carbamazepine monotherapy are
based on the trial data from Nieto-Barrera et al.16
and Zamponi and Cardinali17 combined. Meta-ana-
lyses of the older drugs18,19 suggest that they are of
similar effectiveness with some differences in toxi-
city, with the order of preference being carbama-
zepine, valproate, phenytoin and others. On the
assumption that this is a rational order of prefer-
ence, we have based estimates for valproate, phe-
nytoin and older AED on a slight increase in toxicity
and a slight decrease in effectiveness by comparison
with the drug immediately before it in the
sequence; we used a constant multiplier of 1.05
for withdrawal due to adverse effects and lack of
efficacy and 0.95 for complete seizure freedom to
drive estimates for valproate, phenytoin and older
AED. Table 2 details the proportion estimates
applied for each drug used as first, second, third
and fourth line treatment.
Table 3 shows the proportions used for the various
decisions in the model after the patient reaches
one of the four main treatment outcomes. These
estimates are based upon the limited literature
available.
To calculate the time to ‘treatment failure event’
(withdrawal from drug due to adverse effects or lack
of efficacy) within the model, the RCTs identified byTable 3 Proportions moving into secondary model states
Primary Outcomesa Secondary Outcomes First
1 Try another drug 0.9
No further drugs 0.1
2 Try another drug 0.9
No further drugs 0.1
3 Continue 0
Add-on 0
No further drugs 0.1
Try different drug 0.9
4 Continue indefinitely 0
Withdraw unsuccessfully 0.5
Withdraw unsuccessfully 0.5
a 1 = Intolerable adverse effects; 2 = lack of efficacy; 3 = partial
freedom with tolerable adverse effects.the clinical effectiveness review were explored.
Chadwick 20 provided useful separate survival curves
for discontinuation due to adverse events and for
overall time to withdrawal due to adverse events or
lack of efficacy. However these curves are based on
slightly different patient populations, and the
printed plots are small, with thick lines and a small
gap between the axis, making it especially difficult
to get accurate estimates of the survival rates. It
was therefore not possible to use the Chadwick
paper to accurately estimate survival distributions
and so we chose distributions which were both
consistent with the Chadwick data and which
accorded with clinical advice; that is that unaccep-
table adverse effects will tend to discontinuation
earlier than discontinuation due to lack of effec-
tiveness, often within the titration period, and that
the majority of patients would discontinue by 1 year
due to lack of effect. The distributions are both
Weibull distributions with shape and location para-
meters 0.8 and 2.0 for adverse effects and 1.2 and
6.0 for lack of effect.
It is assumed that patients will continue on AEDs
which are beneficial with acceptable adverse
effects but that at some point later on there will
be further decisions to be made which may include
discontinuation of the drug for various reasons (see
Fig. 3). We have assumed that the time from start-line Second-line Third-line Fourth-line
and beyond
0.95 0.9 0.8
0.05 0.1 0.2
0.95 0.9 0.8
0.05 0.1 0.2
0.05 0.1 0.2
0.3 0.4 0.6
0.05 0.1 0.2
0.6 0.4 0
0 0.1 0.2
0.5 0.45 0.4
0.5 0.45 0.4
efficacy with tolerable adverse effects; 4 = complete seizure
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Table 4 Costsa associated with all AEDs considered in the model
AEDs Cost per mg (pence) Titration dose (per day) Maintenance dose (per day)
Gabapentin 0.023 Age >12 years: 20 mg/kg Age >12 years: 30 mg/kg
Others: 275 mg Others: 1100 mg
Lamotrigine 0.016 Age <12 years: 1.5 mg/kg Age < 12 years: 3 mg/kg
Others: 75 mg Others: 150 mg
Oxcarbazepine 0.013 20 mg/kg 30 mg/kg
Topiramate 0.0146 2 mg/kg 7 mg/kg
Carbamazepine 0.00028 200 mg/day 1—5 years: 300 mg/day
6—10 years: 500 mg/day
11—18 years: 800 mg/day
Valproate 0.00028 Up to 20 kg: 20 mg/kg Up to 20 kg: 20 mg/kg
Phenytoin 0.00089 Over 20 kg: 30 mg/kg Over 20 kg: 35 mg/kg
6 mg.kg 6 mg/kg
a These unit costs are taken from the BNF (September 2002).‘of a’ treatment to the point where a change is made
(switch, add-on or discontinue drug treatment) will
follow a Weibull distribution (shape parameter 4,
and location parameter 2). This distribution gives
few patients making a change within 6 months, with
nearly two-thirds having made a change in 2 years.
We have also assumed, in accordance with clinical
advice that patients achieving complete seizure
freedom who are willing to try to withdraw from
drug treatment will do so, on average, after 2 years
of drug treatment.
Data on drug dose and unit costs estimates were
taken from routine UK sources21—23 and are detailed
in Table 4. Data on more general resource use and
the costs associated with diagnosis of epilepsy were
obtained from clinical experts. In order to obtain
estimates of the resource use and costs to the NHS
for an average child (with and without learning
difficulties) within the health states defined in the
model a survey of clinical experts was conducted.
The resource items upon which data were collected
included: GP consultations, outpatient consulta-
tions, Emergency Department visits, telephone calls
to clinical departments from patients (and family)Table 5 Summary of annual cost for each health state (£)
Health states With learning difficulties
Mean I-Q range
25 50
TOX 1725 804 1130
SEIZ 1648 541 1300
PART 343 196 327
SFREE 273 201 244
WFREE 177 109 175
UNTRT 677 135 218for advice and inpatient stays. Data were collected
from 18 experts, summary of the annual cost asso-
ciated with each health state is presented in
Table 5.
An additional, more speculative, element to the
project was the attempt to undertake a cost-utility
analysis, requiring the use of Quality Adjusted Life
Years (QALYs) i.e. life year gain weighted by a utility
weight (perception of quality of life (QOL) with
regard to health states). Suitable utility estimates
for the modelled health states are not available
from the literature. The views of paediatric con-
sultants concerning the quality of life (QOL) of
children with epilepsy were sought, 25 clinical
experts completed a modified version of the Euro-
QOL EQ-5D instrument.24 The utility values for each
of the health states are presented in Table 6.
Analysis and presentation
Each outcome within the model has associated costs
and effects that are accrued as the patient flows
through the model. Once the patient exits the
model the total cost and outcome for that patientWithout learning difficulties
Mean I-Q range
75 25 50 75
2321 1048 520 894 1328
2532 1365 374 757 1944
438 322 145 281 411
411 323 151 223 363
348 210 130 155 369
789 620 152 218 732
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Table 6 Utilitya values for health states in model
Health states With learning difficulties Without learning difficulties
Mean I-Q range Mean I-Q range
25 50 75 25 50 75
TOX 0.562 0.315 0.673 0.779 0.753 0.689 0.812 0.883
SEIZ 0.670 0.585 0.779 0.779 0.789 0.779 0.812 0.883
PART 0.782 0.779 0.779 0.788 0.915 0.883 1.000 1.000
SFREE 0.825 0.779 0.779 0.815 0.982 1.000 1.000 1.000
WFREE 0.850 0.779 0.815 1.000 1.000 1.000 1.000 1.000
UNTRT 0.702 0.583 0.779 0.779 0.845 0.804 0.883 0.912
a Quality of life value used to weight life years to estimate QALYs.is then calculated. To account for the many dif-
ferent treatment pathways within the model and
the likely small differences between older and
newer AED strategies the model used 10,000 simu-
lated patients for each run and estimated an aver-
age cost per patient at the end of the run. To give
some indication of the sampling variability in the
results the runs of 10,000 simulated patients were
repeated 20 times for each drug strategy. For the
incremental analysis, the costs (and outcomes)
accrued by patients successfully treated on carba-
mazepine are excluded since these are common to
both the baseline strategy and the newer drug
strategies (i.e. all patients are treated initially
with carbamazepine). Thus, the cost and outcome
estimates presented are from the point of failure
on carbamazepine. Another model output is the
average time spent in each treatment outcome for
the each drug sequence. The longer a patient
spends on a drug (or drug combination) the more
that drug is deemed to be effective and acceptable
and so the retention rates (i.e. time to withdrawal)
are also reported. In addition to the cost and ‘time
on outcome’ comparisons, results are also
presented in the form of incremental cost-effec-
tiveness ratios (ICERs), where effectiveness is
measured as QALYs.
The comparison of the 20 mean estimates of the
cost and QALY scores for each newer drug strategy
with the 20 mean estimates for the older drug
strategy give a total of 400 estimates of the incre-
mental cost, incremental QALY score and ICER.
These are reported graphically as scatters on the
cost-effectiveness plane and uncertainty in the
appropriate threshold value of the ICER is explored
using cost-effectiveness acceptability curves
(CEACs). CEACs represent the probability that the
drug strategy is cost-effective given different levels
of willingness-to-pay for the health gains.
To adjust all results to the present value, future
costs are discounted at 6% and future QALY gains
at 1.5%.Sensitivity analysis
The model was re-run using a common discount rate
of 3.5% for both costs and benefits (current UK
Treasury advice). In light of the information from
the RCT evidence that there is no difference in
effectiveness between the older and newer AEDs
but that the new AEDs lead to fewer adverse effects,
the model was re-run using the ‘best’ utility values
for TOX and the ‘worst’ utility values for SEIZ, and
vice versa. This was done in order to maximise the
possible differences between the old and newer
AEDs.Results
If a patient is experiencing unacceptable adverse
effects and poor efficacy then they will switch
relatively quickly to an alternative drug. The model
indicates that, without using the newer AEDs,
patients spend an average of 1.7 and 2.5 years in
outcomes 1 and 2, respectively. Patients spend a
longer period in outcome 3 (3.8 years) but to
achieve complete seizure freedom is relatively rare,
on average only 0.7 years is spent in outcome 4.
Table 7 reports the estimated average number of
years per patient spent in each main treatment
outcome, for the drug sequences considered. The
results reveal no statistically significant differences
between the drug strategies.
Fig. 4 displays the retention rates (i.e. the pro-
portion of patients who remain on the drug in
question over time) for each of the drug sequences
considered in the model. The results show that at
about 1.5 years, approximately one third of patients
have withdrawn from the drug therapy (mainly
because of adverse effect concerns). After 1.5
years, the withdrawal rate remains high as patients
discover that the drug is lacking in efficacy. How-
ever, the rate of withdrawal slows once the AED
therapy has been administered up to 3 years, as the
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.patients who remain on the drug at that point are
experiencing acceptable treatment outcomes.
Fig. 4 demonstrates that there is little difference
between the newer and older AEDs with respect to
the retention rates.
With each run of the model, an estimate of the
incremental cost and incremental QALY gains is
obtained for the comparison of the new drug strat-
egy in question and the baseline strategy. For the 20
runs of the model for each drug strategy, the stan-
dard deviation of the results remained constant (at
2.9) indicating that enough replications of the
model had been run. Fig. 5 presents the results in
the form of cost-effectiveness planes that display
400 (20  20) estimates of the ICERs. In all cases the
baseline strategy is the point of comparison. These
results support the ‘time on outcome’ and retention
rate results in that there is no strong evidence to
suggest that the newer AEDs are associated with
important health benefits. However, Fig. 5 does
indicate a consistent increase in cost for all of the
newer AEDs considered. The scatter plots of ICERs
can be used to construct CEACs for each new drug
strategy. These are displayed in Fig. 6 and indicate
that, for a willingness to pay of £150,000 per QALY,
the probability that any of the newer AEDs is cost-
effective is less than 50%. These results indicate
that the use of new AEDs as first-choice add-on
therapy does not lead to any cost-savings compared
to the baseline strategy.
Re-running the models using the discount rate of
3.5% for both costs and QALYs makes very little
difference to the overall results, the newer AEDs
have a slightly higher cost. Varying the toxicity and
efficacy rates to maximise the difference between
the old and new AEDs strategy also does not have a
marked impact on the overall results.Discussion
The importance of the dual consideration of both
adverse effects and efficacy (in terms of reduction
in seizure rate) when considering the cost-effec-
tiveness of AEDs is highlighted in the literature.25—28
Both effects have been explicitly considered within
the model reported in this paper. In addition, an
important strength of this model is that its structure
and the assumptions made regarding the clinical
decision-making, mirror the realities of patient
management of children with partial epilepsy.
Unlike more conventional and commonly seen mod-
elling approaches, such as Markov models,29 the
individual patient sampling model has no fixed time
cycle and so can accommodate drugs being pre-
scribed for highly variable lengths of time. In this
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Figure 4 First-choice add-on drug retention rate (with valproate).clinical situation, ‘time to withdrawal’ and reten-
tion rates are, therefore, important outcomes to
consider when directly comparing the cost-effec-
tiveness of different drug strategies. While the
model has many strengths, it is necessary to recog-
nise that an important weakness is its limited scope,
for example, the effects of epilepsy surgery, re-
diagnosis and mortality are not considered. The
reason for this is primarily associated with the data
limitations. The prescribing strategies considered
within the model are also based on published pre-
scribing UK guidance in childhood epilepsy and may
not be applicable to other countries.Figure 5 Cost-effectiveness planes presenting results for e
zepine (first-choice add-on therapy); lamotrigine (first-choic
apy). Gabapentin (first-choice add-on therapy).Direct comparison of the sequences of older and
newer AEDs revealed no difference in terms of the
average time spent in the treatment outcomes
specified within the model. The model shows that
patients spend a similar amount of time in all four
outcomes across the drug strategies. Concentrating
on the retention rate of the drugs also revealed
little difference between the old and new drug
strategies indicating that the new drugs are not
producing a favourable outcome with respect to
their adverse-effect and efficacy profile. One inter-
pretation of our findings is that the uncertainty
inherent within the model (i.e. random variation)ach new drug strategy (compared to baseline). Oxcarba-
e add-on therapy); topiramate (first-choice add-on ther-
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Figure 6 Cost-effectiveness acceptability curves for each new drug strategy (compared to baseline).is greater than the differences between the newer
and older AED strategies. Therefore, overall, the
results do not suggest that the use of newer AEDs
in any of the scenarios considered is clearly
cost-effective, but similarly, do not indicate that
they are clearly not cost-effective.
There is no other published evidence that reports
the cost-effectiveness of older versus newer AEDs in
children with focal epilepsies for us to draw com-
parison with. However, there are some studies
which have looked at the cost-effectiveness of these
drugs within an adult population and although the
treatment objectives within this population are
quite different, there may be some merit in com-
paring the results. Schacter et al.30 compared car-
bamazepine and phenytoin with carbamazepine and
tiagabine as add-on therapy in patients with partial
epilepsy. The study found that phenytoin cost US$
810 compared to US$ 958 for tiagabine and that both
drugs (as add-on therapy) had similar efficacy. A
recent review of the cost-effectiveness of older
versus newer drugs in adults with partial epilepsy31
found that beyond a willingness to pay threshold
value of £10,000, it was not possible to determine
which was the most cost-effective AED with any
degree of certainty. While the above studies have
focused on the use of AEDs in adult patients, the
results are in line with those reported in this paper
in that it is not possible to conclude that the newer
AEDs are more cost-effective than the older AEDs.
Epilepsies in children comprise a complex group
of diseases with many different syndromes, treat-
ment options and outcomes. While the majority of
children do respond well to the first treatment
given, for the minority that do not, more evidence
is required on the relative benefits and adverse
effects of any treatment given. The limited trial-
based information available suggests that the newer
drugs, while no more effective than the older drugs,
may be somewhat better tolerated. However, the
analysis and results presented in this paper havedemonstrated that there is insufficient data avail-
able to accurately estimate the nature of this trade-
off, whether in terms of long-term treatment reten-
tion or utility. For any rational evidence-based pre-
scribing strategy to be developed, better
information is required in the form of randomised
controlled trials and utility-based quality of life.
Randomised controlled trials should be conducted
from a public health perspective making relevant
comparisons and incorporating outcomes of interest
to clinicians and patients, with sufficiently long-
term follow-up to determine reliably the clinical
utility of different treatments, particularly with
respect to treatment retention and the balance
between effectiveness and tolerability. Randomised
controlled trials should mirror clinical practice with
respect to diagnosis, focusing on defined syndromes
or; where no syndrome is identified, on groups
defined by specific seizure type(s) and aetiology.References
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